Dementia with Lewy Bodies

Detailed Overview

DLB is the second most common neurodegenerative dementia after Alzheimer's disease. Pathologically, it is defined by the widespread aggregation of alpha-synuclein protein into intraneuronal inclusions called Lewy bodies throughout the cerebral cortex, limbic system, and brainstem. Clinically, it uniquely blends the cognitive phenotype of Alzheimer's with the motor phenotype of Parkinson's disease. A hallmark characteristic is extreme sensitivity to neuroleptic (antipsychotic) medications, which can cause severe, irreversible, and potentially fatal motor worsening.

Epidemiology & Demographics

Accounts for 10-15% of all dementia cases. Affects approximately 1.4 million individuals in the US. More common in men than women. Typical onset is between 70 and 80 years of age.

Etiological Mechanism

The exact cause is unknown, but it is classified as an alpha-synucleinopathy. Most cases are sporadic, though rare familial forms exist linked to mutations in the SNCA or GBA genes.

Primary Causes

Abnormal aggregation of alpha-synuclein protein forming Lewy bodies and Lewy neurites.

• Advanced Age: The most significant risk factor; incidence rises sharply after age 70.
• REM Sleep Behavior Disorder (RBD): A very strong prodromal marker; acting out dreams can precede dementia by 10-20 years.
• Genetics: Presence of the APOE4 allele or GBA mutations increases risk.

Misfolded alpha-synuclein proteins aggregate into insoluble fibrils, forming Lewy bodies within the cytoplasm of neurons. Unlike Parkinson's disease, where Lewy bodies are initially confined to the substantia nigra, in DLB they rapidly disseminate throughout the neocortex (causing dementia) and limbic system (causing hallucinations). This widespread pathology disrupts multiple neurotransmitter systems. There is a profound deficit in cortical acetylcholine (greater than in Alzheimer's), driving the cognitive fluctuations and visual hallucinations. Concurrently, there is a moderate loss of dopamine in the nigrostriatal pathway, resulting in parkinsonian rigidity and bradykinesia. Co-existing Alzheimer's pathology (amyloid plaques) is present in >50% of cases and accelerates the decline.

Characteristic Clinical Presentation

• Fluctuating Cognition: Pronounced variations in attention and alertness, often described as 'good days and bad days' or episodes of blank staring and daytime drowsiness.
• Visual Hallucinations: Recurrent, well-formed, and highly detailed visual hallucinations (e.g., seeing silent people or animals in the room) that occur early in the disease.
• REM Sleep Behavior Disorder: Loss of normal muscle atonia during REM sleep, leading patients to vividly vocalize or physically act out their dreams (punching, kicking).
• Parkinsonism: Spontaneous development of bradykinesia, limb rigidity, and an unsteady gait. (Resting tremor is less common than in classic PD).

Physical Examination Signs

• Cogwheel rigidity on passive limb movement
• Masked facies (hypomimia)
• Severe orthostatic hypotension (autonomic dysfunction)
• Visuospatial deficits on bedside testing (inability to draw intersecting pentagons or a clock face)

• Severe Neuroleptic Sensitivity: Administration of typical (haloperidol) or some atypical antipsychotics can cause an acute, severe, life-threatening parkinsonian crisis or neuroleptic malignant syndrome.
• Recurrent Falls: Due to a combination of parkinsonian gait, orthostatic hypotension, and visuospatial impairment.
• Autonomic Failure: Severe constipation, urinary incontinence, and orthostasis.

Diagnostic Criteria & Guidelines

McKeith Criteria for Probable DLB: Dementia PLUS two or more core clinical features (fluctuating cognition, visual hallucinations, REM sleep behavior disorder, parkinsonism) OR one core feature PLUS one indicative biomarker (abnormal DAT scan).

Differential Diagnosis

• Alzheimer's Disease (prominent early memory loss, lack of parkinsonism or early hallucinations)
• Parkinson's Disease Dementia (PDD) (Parkinsonism starts >1 year BEFORE dementia onset; in DLB, dementia is concurrent or precedes parkinsonism)
• Vascular Dementia (stepwise decline, evidence of prior strokes)
• Delirium (acute onset due to medical illness, UTI, or medications)

Laboratory Tests & Biomarkers

• Routine Dementia Panel (B12, TSH, RPR, HIV): Normal. Used to rule out reversible causes of cognitive decline.

Imaging Modalities & Findings

• Dopamine Transporter (DAT) SPECT Scan:
• Brain MRI:
• Polysomnography:

• Prodromal
  Mild cognitive impairment, prominent REM sleep behavior disorder, hyposmia, and mild dysautonomia.
• Early Dementia
  Emergence of detailed visual hallucinations and mild parkinsonism. Loss of independence in complex daily activities.
• Advanced Dementia
  Severe cognitive decline, frequent falls due to profound parkinsonism, severe dysphagia, completely dependent for care.

Second-Line & Adjunctive Therapy

If hallucinations are severe, distressing, and unresponsive to donepezil: VERY cautious use of specific atypical antipsychotics with the lowest D2 affinity (Quetiapine 12.5-25 mg at bedtime or Pimavanserin 34 mg daily). For refractory RBD: Clonazepam 0.5 mg at bedtime (use with caution due to fall risk).

Surgical & Procedural Management

None. Deep Brain Stimulation (DBS) is contraindicated in DLB due to the high risk of worsening cognitive decline.

Recommended Lifestyle Changes

• Implement rigorous fall-prevention strategies in the home (remove rugs, install grab bars).
• Physical therapy for gait training and maintaining mobility.
• Caregiver education regarding the profound daily fluctuations in the patient's abilities.

Patient Counseling & Advice

Thoroughly educate the family that the patient is NOT 'faking' their good or bad days—fluctuations are a core feature of the brain disease. Explicitly warn the family and document in the chart: THE PATIENT MUST NEVER BE GIVEN HALDOL OR TYPICAL ANTIPSYCHOTICS in an emergency room or hospital setting.

Follow-Up & Monitoring Schedule

Frequent outpatient monitoring to balance the "teeter-totter" of treatments (e.g., levodopa helps movement but worsens hallucinations; antipsychotics help hallucinations but destroy movement). Monitor orthostatic blood pressures.

Preventive Strategies

No known preventative measures exist.

Progressive and incurable. Progression is generally more rapid than Alzheimer's disease. Median survival is roughly 5 to 8 years from diagnosis, often terminating in complications like aspiration pneumonia or fatal falls.